CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the closing of ...
BOSTON--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful ...
Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback